EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 46.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,586 shares of the company’s stock after selling 37,601 shares during the period. Jane Street Group LLC owned approximately 0.08% of EyePoint Pharmaceuticals worth $340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its stake in EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after purchasing an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC purchased a new stake in EyePoint Pharmaceuticals during the 2nd quarter valued at about $94,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of EyePoint Pharmaceuticals by 271.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after buying an additional 7,953 shares during the last quarter. Cyndeo Wealth Partners LLC purchased a new stake in shares of EyePoint Pharmaceuticals in the third quarter worth about $100,000. Finally, Arizona State Retirement System boosted its stake in shares of EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $115,000 after buying an additional 1,171 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Performance

EYPT opened at $9.11 on Thursday. The business’s 50-day simple moving average is $8.96 and its 200-day simple moving average is $8.99. EyePoint Pharmaceuticals, Inc. has a one year low of $6.90 and a one year high of $30.99. The stock has a market capitalization of $621.77 million, a P/E ratio of -4.56 and a beta of 1.49.

Analysts Set New Price Targets

A number of analysts have recently commented on EYPT shares. Citigroup started coverage on EyePoint Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $33.00 target price on the stock. Robert W. Baird reduced their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, November 11th. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Chardan Capital upped their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Scotiabank started coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.